Divi’s Laboratories (DIVISLAB) has delivered a very strong

Divi’s Laboratories (DIVISLAB) has delivered a very strong Q1 FY27. Revenue from operations increased 27.8% YoY to ₹3,080 crore, while consolidated PAT jumped 65.5% to ₹902 crore. Operating profitability improved sharply, with operating profit rising about 83% YoY, indicating strong operating leverage and better margins. The major positive is the company's strong positioning in APIs, generic ingredients and custom synthesis/CDMO, where higher-value products and better capacity utilisation can support future growth. Q1 also saw PAT margin expand substantially, reflecting improved profitability. Another positive is the improving outlook for custom synthesis and CDMO, which can provide longer-term growth beyond traditional API sales. Broker sentiment has also remained constructive; Citi recently reiterated a Buy view on Divi’s, highlighting its long-term growth potential.